| Literature DB >> 25243129 |
Lilla Ordögh1, Andrea Vörös1, István Nagy1, Eva Kondorosi2, Attila Kereszt1.
Abstract
The increasing number of multidrug-resistant microbes now emerging necessitates the identification of novel antimicrobial agents. Plants produce a great variety of antimicrobial peptides including hundreds of small, nodule-specific cysteine-rich NCR peptides that, in the legume Medicago truncatula, govern the differentiation of endosymbiotic nitrogen fixing bacteria and, in vitro, can display potent antibacterial activities. In this study, the potential candidacidal activity of 19 NCR peptides was investigated. Cationic NCR peptides having an isoelectric point above 9 were efficient in killing Candida albicans, one of the most common fungal pathogens of humans. None of the tested NCR peptides were toxic for immortalized human epithelial cells at concentrations that effectively killed the fungus; however, at higher concentrations, some of them inhibited the division of the cells. Furthermore, the cationic peptides successfully inhibited C. albicans induced human epithelial cell death in an in vitro coculture model. These results highlight the therapeutic potential of cationic NCR peptides in the treatment of candidiasis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25243129 PMCID: PMC4163382 DOI: 10.1155/2014/320796
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
List of NCR peptides used in this study. Length: number of amino acids; MW: molecular weight in Da; pI: isoelectronic point.
| Peptide | Sequence of the mature peptide | Length | MW | pI |
|---|---|---|---|---|
| NCR168 | YPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT | 41 | 4476 | 3.61 |
| NCR095 | ELVCDTDDDCLKFFPDNPYPMECINSICLSLTD | 33 | 3770 | 3.62 |
| NCR051 | EEDIGGHLECVEDEDCMEESCPIFSVHKCKNSGCECDEMFR | 41 | 4684 | 4.14 |
| NCR235 | DTDPFAFCIKDSNCGQDLCTSPNEVPECRLLKCQCIKS | 38 | 4223 | 4.53 |
| NCR224 | KDLPFNICEKDEDCLEFCAHDKVAKCMLNICFCF | 34 | 3987 | 4.65 |
| NCR001 | AFERTETRMLTIPCTSDANCPKVISPCHTKCFDGFCGWYIEGSYEGP | 47 | 5263 | 5.01 |
| NCR084 | FATGMPCKTDKECPNTSTHKYKCINDDCFCFYIYWPLGNSLV | 42 | 4856 | 6.71 |
| NCR169 | EDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK | 38 | 4565 | 8.45 |
| NCR055 | VNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR | 43 | 4759 | 9.21 |
| NCR035 | SFLGTFISSCKRDKDCPKLYGANFRCRKGTCVPPI | 35 | 3910 | 9.42 |
| NCR192 | MKNGCKHTGHCPRKMCGAKTTKCRNNKCQCVQL | 33 | 3708 | 9.54 |
| NCR137 | MTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK | 35 | 4018 | 9.7 |
| NCR147 | IYFPVSRPCITDKDCPNMKHYKAKCRKGFCISSRVR | 36 | 4249 | 9.76 |
| NCR280 | MRVLCGRDGRCPKFMCRTFL | 20 | 2390 | 9.8 |
| NCR183 | ITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR | 42 | 4979 | 10.1 |
| NCR247 | RNGCIVDPRCPYQQCRRPLYCRRR | 24 | 3009 | 10.15 |
| NCR044 | AFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR | 36 | 4318 | 10.32 |
| NCR030 | AFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR | 36 | 4197 | 10.37 |
| NCR335 | RLNTTFRPLNFKMLRFWGQNRNIMKHRGQKVHFSLILSDCKTNKDCPKLRRANVRCRKSYCVPI | 64 | 7736 | 11.22 |
Minimal inhibitory concentration (μg/mL) of the NCR peptides against C. albicans strains WO-1 and Sc5314 after 24 hours of treatment in vitro.
| Peptide | WO-1 | Sc5314 |
|---|---|---|
| NCR168 | — | — |
| NCR095 | — | — |
| NCR051 | — | — |
| NCR235 | — | — |
| NCR224 | — | — |
| NCR001 | — | — |
| NCR084 | — | — |
| NCR169 | — | — |
| NCR055 | 50 (±4) | 50 (±3) |
| NCR035 | — | — |
| NCR192 | 10 (±2) | 12.5 (±1) |
| NCR137 | 20 (±2) | 25 (±2) |
| NCR147 | 19 (±9) | 12.5 (±2) |
| NCR280 | 19 (±6) | 25 (±3) |
| NCR183 | 19 (±6) | 12.5 (±1.5) |
| NCR247 | 14 (±9) | 25 (±2) |
| NCR044 | 11 (±3) | 12.5 (±1) |
| NCR030 | 15 (±7) | 25 (±5) |
| NCR335 | 11 (±1) | 12.5 (±2.5) |
—: no growth inhibition was observed.
Minimal fungicidal concentration (μg/mL) of the active NCR peptides against C. albicans WO-1 after 3 or 24 hours of treatments.
| Peptide | 3 h | 24 h |
|---|---|---|
| NCR192 | 8 (±3,5) | 9 (±4) |
| NCR137 | 20 (±2.5) | 25 (±3) |
| NCR147 | 8 (±6.5) | 9 (±4) |
| NCR280 | 10 (±2) | 8 (±3) |
| NCR183 | 16.5 (±12) | 15.5 (±13) |
| NCR247 | 14 (±10) | 16.5 (±13) |
| NCR044 | 11 (±2) | 6.25 (±1) |
| NCR030 | 12.5 (±2) | 16.5 (±5) |
| NCR335 | 7 (±1) | 8 (±2) |
Figure 1NCR provoked morphological changes and localization of fluorescently labeled NCR peptides in C. albicans cells and pseudohyphae. ((a)–(h)) Pseudohyphal C. albicans WO-1 cells were either mock treated (a), (b) or treated with NCR335 (c), (d); NCR247 (e), (f); NCR192 (g), (h) peptides at 25 μg/mL concentration for 2 hours. Differential interference contrast (DIC) ((a), (c), (e), and (g)) and fluorescent ((b), (d), (f), and (h)) images obtained after FM4-64 (cell membrane; red) and DAPI labeling (DNA; blue). ((i)–(o)) Planktonic cells were treated with 5 μg/mL of FITC-conjugated NCR035 (i), (j) or NCR247 (k)–(o) and the localization of the peptides was monitored with confocal microscopy 3 hours after the treatment. DIC ((i), (k), and (m)) and fluorescent images ((j), (l), and (n)); (o) merged image of (m), (n). Scale bars: (a) 20 μm, (i) 100 μm.
Figure 2Time course of calcein release from NCR-treated C. albicans WO-1 cells. Calcein-loaded cells were treated with the peptides at 50 μg/mL concentration and the fluorescence of the released calcein was measured with a microtiter plate reader (excitation 485 nm, emission 530 nm).
Figure 3Viability/metabolic activity (a) and proliferation ability (b) of PK E6/E7 vaginal epithelial cells after NCR treatment. (a) The amount of formazan formed after treatment was measured by the absorbance at 560 nm. (b) The relative amount of viable, attached cells 40 hours after treatment was measured by RTCA. The number of cells that were attached when peptides were replaced with CKM after the treatment was considered as 100%. PBgluc: mock treatment; primycin: cytotoxic control. *Significant (P < 0.0001) difference between the connected treatments. •The observed cell number significantly (P < 0.0001) differs from that of the PBgluc and primycin controls.
Figure 4Effects of the NCR peptides on PK E6/E7 vaginal epithelial cell—C. albicans coculture. The relative amount of viable, attached cells 40 hours after treatment was measured by RTCA as in Figure 3. 25 and 50 mg/L indicate treatments of the human cells only with peptides; C. albicans 25 μg/mL and C. albicans 50 μg/mL show the result from treatments of the cocultures with peptides at 25 μg/mL or 50 μg/mL concentrations, respectively. *Significant (P < 0.0001) difference between the connected treatments. •The observed cell number significantly (P < 0.0001) differs from that of the mock (PBgluc) and infected (C. albicans) controls.